Current Search:  protein-protein interactions (x)

View All Items

  • CSV Spreadsheet
(1 - 2 of 2)
Unraveling PDI and its Interaction with AB Toxins
Title
Unraveling PDI and its Interaction with AB Toxins.
Creator
Guyette, Jessica, Teter, Kenneth, Self, William, Jewett, Travis, Tatulian, Suren, University of Central Florida
Abstract / Description
Protein disulfide isomerase (PDI) is an essential endoplasmic reticulum (ER) protein that acts as both an oxidoreductase and chaperone. It exhibits substantial flexibility and undergoes cycles of unfolding and refolding in its interaction with cholera toxin (Ctx), which is a unique property of PDI. This unfolding allows PDI to disassemble the Ctx holotoxin, which is required for Ctx activity. Here, we investigated the unfolding and refolding property of PDI and how this affects its...
Show moreProtein disulfide isomerase (PDI) is an essential endoplasmic reticulum (ER) protein that acts as both an oxidoreductase and chaperone. It exhibits substantial flexibility and undergoes cycles of unfolding and refolding in its interaction with cholera toxin (Ctx), which is a unique property of PDI. This unfolding allows PDI to disassemble the Ctx holotoxin, which is required for Ctx activity. Here, we investigated the unfolding and refolding property of PDI and how this affects its interaction with bacterial toxins. PDI showed remarkable redox-linked conformational resilience that allows it to refold after being thermally stressed. Deletion constructs of PDI showed that both active domains play opposing roles in stability, and can both refold from an unfolded state, indicating that either domain could unfold during its interaction with Ctx. Its ability to refold suggests that the cycle of unfolding and refolding with Ctx is a normal mechanism that prevents protein aggregation. Disruption of this cycle with the polyphenol, quercetin-3-rutinoside, prevented the disassembly of Ctx, which blocked Ctx intoxication of cultured cells. Loss of PDI function was also found to inhibit intoxication with Escherichia coli heat-labile toxin but not with ricin and Shiga toxins. Toxin structure also contributes to efficiency of PDI binding and disassembly, which may explain the differential potencies between toxins. While Ctx and Ltx share similar structures, Ctx is more potent and efficiently disassembled compared to Ltx. We believe that PDI-mediated disassembly is the rate-limiting step in intoxication, thus dictating toxin potency. Overall, PDI can be targeted for a potential therapeutic for many bacterial toxins because of its unique unfolding properties and its key role in cell intoxication.
Show less
Date Issued
2019
Identifier
CFE0007646, ucf:52511
Format
Document (PDF)
PURL
http://purl.flvc.org/ucf/fd/CFE0007646
DEVELOPMENT OF A FLUORESCENT DRUG SCREENING PLATFORM FOR INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS PROTEIN-PROTEIN INTERACTIONS
Title
DEVELOPMENT OF A FLUORESCENT DRUG SCREENING PLATFORM FOR INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS PROTEIN-PROTEIN INTERACTIONS.
Creator
Versfeld, Zina, Rohde, Kyle, University of Central Florida
Abstract / Description
Tuberculosis (TB) is a respiratory disease caused by Mycobacterium tuberculosis (Mtb) that kills around 1.3 million people annually. Multi-drug resistant TB (MDR-TB) strains are increasingly encountered, in part resulting from shortcomings of current TB drug regimens that last between six to nine months. Patients may stop taking the antibiotics during their allotted regimen, leading to drug resistant TB strains. Novel drug screening platforms are therefore necessary to find drugs effective...
Show moreTuberculosis (TB) is a respiratory disease caused by Mycobacterium tuberculosis (Mtb) that kills around 1.3 million people annually. Multi-drug resistant TB (MDR-TB) strains are increasingly encountered, in part resulting from shortcomings of current TB drug regimens that last between six to nine months. Patients may stop taking the antibiotics during their allotted regimen, leading to drug resistant TB strains. Novel drug screening platforms are therefore necessary to find drugs effective against MDR-TB. In order to discover compounds that target under-exploited pathways that may be essential only in vivo, the proposed screening platform will use a novel approach to drug discovery by blocking essential protein-protein interactions (PPI). In Mtb, PPI can be monitored by mycobacterial protein fragment complementation (M-PFC). This project will re-engineer the M-PFC assay to include the red fluorescent mCherry reporter for increased efficiency and sensitivity in high-throughput screening applications. To optimize the mCherry assay, we have developed fluorescent M-PFC reporter strains to monitor distinct PPI required for Mtb virulence: homodimerization of the dormancy regulator DosR. A drug screen will then identify novel compounds that inhibit this essential PPI. The screen will involve positional-scanning combinatorial synthetic libraries, which are made up of chemical compounds with varying side chains. This work will develop novel tools for TB drug discovery that could identify new treatments for the emerging world threat of MDR-TB.
Show less
Date Issued
2015
Identifier
CFH0004785, ucf:45369
Format
Document (PDF)
PURL
http://purl.flvc.org/ucf/fd/CFH0004785